While Holt's departure has led to the appointment of Aaron Berg, Amarin's (AMRN) President of the U.S. Business, as his successor, Vascepa's commercial update concerns a major national pharmacy ...

“The data to be presented at the AHA Scientific Sessions continues to affirm the clinical utility and value of VASCEPA/VAZKEPA, not only in the overall REDUCE-IT trial population, but also across ...

Cash and Investments: $306 million as of September 30, 2024. VASCEPA/VAZKEPA has significant growth potential globally, ...

Amarin’s cardio drug Vascepa (icosapent ethyl) has been granted Priority Review designation by the FDA after trial results showed it could reduce the risk of major cardio events by up to 25%.

Year to date, the stock has plunged 30.8% compared with the industry’s decline of 3.2%. Net product revenues from Vascepa, the company’s sole marketed drug, in the third quarter, were $41.9 million, ...

Amarin is on course to significantly increase the number of patients eligible for treatment with its purified fish oil drug Vascepa after an FDA advisory committee voted in favour of an expanded ...

Net product revenues from Vascepa, the company’s sole marketed drug, in the third quarter, were $41.9 million, down 36% year over year. U.S. product revenues from Vascepa totaled $30.6 million ...